Menu Close
Close
Apply Now
Neurological Regeneration Therapy

NeuroBoost Protocol

A physician-supervised exosome protocol using UC-MSC derived extracellular vesicles, administered intranasally to support neurological tissue health. Preclinical evidence suggests intranasal delivery may allow exosomes to reach the central nervous system via the olfactory pathway.

Start Your Evaluation
neuroboost
Intranasal administration under physician supervision.
30–150 nm

Diameter of the extracellular vesicles delivered in the protocol.

UC-MSC

Umbilical-cord mesenchymal stem cells, the source of the exosomes.

Intranasal

Non-invasive route, studied for access via the olfactory and trigeminal pathways.

nebulized exosomes therapy neuroboost
The Procedure

What exosomes are, and why we use umbilical cord.

What are exosomes?

Exosomes are nano-sized vesicles (30–150 nanometers) naturally secreted by umbilical cord mesenchymal stem cells. These extracellular vesicles carry a bioactive payload of proteins, RNA, lipids, and growth factors that function as intercellular communication signals, influencing processes such as neuroinflammation modulation, neuroprotection, and cellular repair signaling.

Why umbilical cord?
UC-MSC-derived exosomes are sourced ethically from donated umbilical cord tissue, with no harm to mother or newborn. Their neonatal origin is associated with a favorable biological activity profile and low immunogenicity. In neurological research, they are studied for their neuroprotective signaling factors, anti-inflammatory cytokines, and growth factors that may support neural health.
Administration

A non-invasive route to the central nervous system.

NeuroBoost exosomes are administered intranasally, utilizing the olfactory and trigeminal neural pathways, which connect the nasal mucosa to the central nervous system, as a potential route for CNS access.

Preclinical evidence suggests this pathway may allow exosome-carried bioactive factors to reach brain tissue without requiring systemic circulation. This is an investigational approach; individual responses vary and are not guaranteed.

neuroboost at omnistem
Exosome Signaling

Supporting neural health through cellular communication.

Neurological conditions, aging, and brain injuries disrupt the communication networks that maintain cognitive function and neural health. UC-MSC-derived exosomes are being studied for their potential to:
  • Support the reactivation of neural repair signaling pathways.
  • Modulate chronic neuroinflammation at the cellular level.
  • Influence synaptic plasticity and neural connectivity.
  • Contribute to neurogenic signaling environments in affected tissue.
  • Carry neuroprotective factors that may help support neurons against inflammatory stress.
Intranasal administration is designed to access these pathways via the olfactory route, potentially without requiring systemic circulation.
Safety Profile

An acellular protocol, assessed patient by patient.

Because NeuroBoost utilizes acellular exosomes, there is no risk of uncontrolled cellular proliferation, and the risk of immune rejection is low given the established immunological profile of UC-MSC-derived material.

  • Acellular material, no risk of uncontrolled cellular proliferation.
  • Low immune-rejection risk, given the established profile of UC-MSC-derived vesicles.
  • Individual safety is assessed through physician evaluation prior to treatment.
  • Peer-reviewed preclinical research suggests influence on neural behavior via paracrine signaling. Clinical evidence in humans remains early-stage; results are not guaranteed.
Candidacy

Who may be considered for this protocol.

Candidacy is determined through individual physician evaluation. This protocol may be appropriate for:

Limited response to conventional care
Patients managing neurological conditions who have not achieved adequate response with conventional approaches, and are seeking a complementary, physician-supervised regenerative option.
Neuroinflammatory objectives
Patients with neuroinflammatory conditions where reducing CNS-level inflammation is a clinical objective, and for whom this approach has been deemed appropriate through medical evaluation.
A non-invasive preference
Patients seeking a non-invasive, non-surgical approach to support neurological health, with realistic expectations about the investigational nature of the therapy.
A favorable safety profile
Patients seeking a minimally invasive regenerative option with a favorable safety profile, as assessed through individual physician evaluation.
Frequently asked

Conditions under investigation.

The areas below are subjects of preclinical and early-stage research. NeuroBoost is offered as an investigational, complementary protocol following thorough physician evaluation, never as a replacement for neurologist-managed care.

Neurodegenerative conditions, including Alzheimer's disease, Parkinson's disease, and ALS, represent areas of significant unmet medical need. UC-MSC-derived exosomes are being studied in preclinical models for their potential neuroprotective and anti-inflammatory signaling properties. Clinical evidence in human patients with these conditions is preliminary and evolving.

Stroke recovery is a complex, multifactorial process. Preclinical and early-stage human research on exosome-based therapies suggests potential for supporting neuroinflammation modulation and synaptic repair signaling in post-stroke settings.

TBI and post-concussion conditions are being studied as potential applications for exosome-based therapies, given their anti-inflammatory signaling properties. Neural repair effects are investigational; clinical evidence in humans is early-stage.

Conditions such as multiple sclerosis and autoimmune encephalitis involve immune-mediated neurological damage. UC-MSC-derived exosomes are being studied for their potential to modulate neuroinflammatory pathways.

Pediatric neurological conditions, including cerebral palsy, developmental delays, and autism spectrum disorders, represent areas of early-stage investigation for exosome-based therapies. Clinical evidence in pediatric populations is very preliminary.

BEGIN YOUR EVALUATION

Your case. In our hands.
Within 48 hours.

A physician on the OmniStem medical team will review your clinical profile individually and prepare an initial assessment. What follows is a medical conversation, no obligation.

Start Your Evaluation